PharMED BPT
With its superior flex life characteristics, PharMed BPT tubing simplifies biopharmaceutical manufacturing processes by reducing production downtime due to pump tubing failure. The excellent wear properties of PharMed BPT tubing also can lead to reduced erosion of the tubing interior walls, improving the overall efficiency of filtering systems.
- Outlasts silicone tubing in peristaltic pumps
- Withstands repeated autoclaving
- Withstands repeated CIP and SIP cleaning and sterilization
- Documented Biocompatibility
- Multiple Manufacturing sites
- Cell harvest and media process systems
- Bioreactor process lines
- Production filtration and fermentation
- Sterile filling
- Shear-sensitive fluid transfer
- Diagnostics and laboratory testing
Related Products
At Liquidyne, we prioritize our commitment to quality and consistency. In 2017 we achieved ISO 9001:2015 Quality Management System certification to ensure we can repeatedly deliver consistently high-quality products and solutions. Being an ISO 9001 facility, together with our USP Class VI Testing, ASME Bioprocessing Equipment (BPE), and EHEDG certification guarantee, we have the methodologies to assure quality. We will quickly and accurately rectify any issues if any of our products are ever in non-conformance.
"Thanks so much! What a quick turn around. It is a pleasure working with Liquidyne."
Process Development Manager
"I received the cart yesterday, thanks for the fast delivery! It feels sturdy. I sat on it. It does not bounce. It is also easy to clean and wipe or wash down."
Vice President, Analytical Development and Manufacturing
"Thanks again for reacting so quickly and meeting me halfway with the element. We will be able to get installed and have things keep moving overnight with the night crew. The little things like this are always greatly appreciated when working with Liquidyne."
Chemical Engineer
“This pump cut our processing time from 3 days to 1 shift. I’m not giving this pump back. You will have to come and get it if you want it... and that won’t likely happen.”
VP Antibody Manufacturing